跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 103,689 条关于
“HR+/HER2− metastatic breast cancer”
全部
103,689
临床试验
84,359
药物
2,686
机构
1,177
资讯
15,467
4年前
FDA Grants Priority Review for Trodelvy in HR+/HER2- Metastatic Breast Cancer Following Positive Survival Data
10个月前
Gilead's Trodelvy Fails Primary Endpoint in First-Line HR+/HER2- Metastatic Breast Cancer Trial
去年
BRACELET-1 Trial Shows Promise for Oncolytic Virus Pelareorep in HR+ Breast Cancer
去年
Real-World Data Show No Overall Survival Difference Among First-Line CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
4个月前
Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer
去年
Oncolytics Biotech's Pelareorep Shows Promising Survival Benefit in Breast Cancer
去年
Sacituzumab Govitecan Demonstrates Efficacy in HR+/HER2- Metastatic Breast Cancer
2年前
Patritumab Deruxtecan Shows Promise in HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Resistance
去年
Puma Biotechnology Initiates Phase 2 Trial of Alisertib for HR+/HER2- Metastatic Breast Cancer
去年
Puma Biotechnology Initiates Phase II Trial of Alisertib for HR+/HER2- Metastatic Breast Cancer
第 1 页，共 1547 页
上一页
下一页
